Aktis Oncology, Inc.
AKTS
Rank in Stocks
#9263
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to... Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Share Price
$16.37
Last synced: 2026-11-09
Market Cap
$879.83M
Change (1 day)
3.48%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aktis Oncology, Inc. (AKTS)
Category
Healthcare
EPS for Aktis Oncology, Inc. (AKTS)
EPS as of June 2026 TTM: $-1.05
According to Aktis Oncology, Inc.'s latest financial reports, its current EPS (TTM) is $-1.05. At the end of 2025 the company had an EPS of $-1.19, an increase over its 2024 EPS of $-1.26.
EPS history for Aktis Oncology, Inc. from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.05 | -11.76% |
| 2025 | $-1.19 | -5.56% |
| 2024 | $-1.26 | 53.66% |
| 2023 | $-0.82 | 60.78% |
| 2022 | $-0.51 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,591.43% |
US
|
|
| $-7.07 | 573.33% |
US
|
|
| $-5.29 | 403.81% |
AU
|
|
| $12.88 | -1,326.68% |
BE
|
|
| $21.56 | -2,153.33% |
NL
|
Questions about Aktis Oncology, Inc.'s earnings per share (EPS)
What is Aktis Oncology, Inc.'s earnings per share (EPS)?
Aktis Oncology, Inc.'s earnings per share (EPS) over the last twelve months is $-1.05, as of Jun 2026.
What was Aktis Oncology, Inc.'s earnings per share (EPS) in 2025?
In 2025, Aktis Oncology, Inc.'s earnings per share (EPS) was $-1.19, compared with $-1.26 in 2024.
How has Aktis Oncology, Inc.'s earnings per share (EPS) changed since 2022?
From 2022 to 2025, Aktis Oncology, Inc.'s earnings per share (EPS) was highest in 2022 ($-0.51) and lowest in 2024 ($-1.26).
How does Aktis Oncology, Inc.'s earnings per share (EPS) compare with similar companies?
Aktis Oncology, Inc.'s earnings per share (EPS) ($-1.05) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.